DL-AP5

SKU: orb1219455

Description

DL-AP5 is the racemic version of the selective N-methyl-D-aspartate (NMDA) receptor antagonist,with anticonvulsant.DL-AP5, a competitive NMDAR antagonist, on tramadol state-dependent memory. A single-trial step-down passive avoidance task was used for the assessment of memory retrieval in adult male NMRI mice. Post-training i.p. administration of an atypical μ-opioid receptor agonist, tramadol (2.5 and 5 mg/kg), dose-dependently induced impairment of memory retention. Pre-test injection of tramadol (2.5 and 5 mg/kg) induced state-dependent retrieval of the memory acquired under post-training administration of tramadol (5 mg/kg) influence. Pre-test intra-CA1 injection of NMDA (10-5 and 10-4 μg/mouse) 5 min before the administration of tramadol (5 mg/kg, i.p.) dose-dependently inhibited tramadol state-dependent memory. Pre-test intra-CA1 injection of DL-AP5 (0.25 and 0.5 μg/mouse) reversed the memory impairment induced by post-training administration of tramadol (5 mg/kg). Pre-test administration of DL-AP5 (0.25 and 0.5 μg/mouse) with an ineffective dose of tramadol (1.25 mg/kg) restored the retrieval and induced tramadol state-dependent memory. It can be concluded that dorsal hippocampal NMDAR mechanisms play an important role in the modulation of tramadol state-dependent memory.

Key Properties

• CAS Number: 76326-31-3
• MW: 197.13
• Purity: >98% (HPLC)
• Formula: C₅H₁₂NO₅P
• SMILES: NC(CCCP(O)(O)=O)C(O)=O
• Target: NMDAR
• Solubility: In Vitro: H2O : 33.33 mg/mL (169.08 mM)

Bioactivity

• In Vivo:
  DL-AP5 (0-10 μg/rat, Intra-CA1) significantly decreases the effect of NMDA. DL-AP5 (0-10 nmol, Intracerebroventricular injection) causes a dose-dependent increase in food consumption. DL-AP5 (5 nmol, Intracerebroventricular injection) attenuates the decreased food consumption induced by the intracerebroventricular injection of ghrelin. Animal model: Male Wistar rats (180-230 g). Dosage: 1, 3.2 and 10 μg/rat. Administration: Injected into the intra-dorsal hippocampal (intra-CA1) immediately after shock administration, once. Result: Significantly decreased the effect of NMDA (10-2 μg/rat, intra-CA1) with significant interaction. Animal model: Broilers cockerels (3-h fooddeprived (FD3), n = 8 for each group). Dosage: 0, 2.5, 5, and 10 nmol; in a volume of 10 μL. Administration: Intracerebroventricular injection. Result: Caused a dose-dependent increase in food consumption which was significant for 5 and 10 nmol doses. Animal model: Broilers cockerels (3-h fooddeprived (FD3), n = 8 for each group). Dosage: 5 nmol. Administration: Intracerebroventricular injection, followed by ghrelin (0.6 nmol). Result: Attenuated the decreased food consumption induced by the intracerebroventricular injection of ghrelin.
• In Vitro:
  DL-AP5 (100 μM) partially prevents glutamate-induced increase in Arc/Arg3.1 protein levels. DL-AP5 decreases the NMDA-induced Arc/Arg3.1 upregulation.

Storage & Handling

• Storage: Storage temperature: -20°C. Stability: ≥ 2 years
• Expiration Date: 12 months from date of receipt.
• Disclaimer: For research use only

Quick Database Links

Gene Symbol

NMDAR